Pharmala Biotech Holdings Inc. (CSE:MDMA)

Market Cap	11.95M
Revenue (ttm)	420.81K
Net Income (ttm)	-2.04M
Shares Out	108.62M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	55,115
Average Volume	263,208
Open	0.1150
Previous Close	0.1100
Day's Range	0.1150 - 0.1150
52-Week Range	0.0850 - 0.3400
Beta	0.90
RSI	46.40
Earnings Date	Dec 19, 2025

About Pharmala Biotech Holdings

Pharmala Biotech Holdings Inc., doing business as PharmAla, a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Nicholas Kadysh
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: MDMA

Financial Performance

In 2024, Pharmala Biotech Holdings's revenue was 1.04 million, an increase of 94.60% compared to the previous year's 532,003. Losses were -823,596, 5.61% more than in 2023.